Geniner
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Geniner - overview
Established
2020
Location
Seoul, -, South Korea
Primary Industry
Biotechnology
About
Founded in 2020 and based in Seoul, South Korea, Geniner operates as a biotechnology firm that develops animal vaccines, antibiotic alternatives, and antibody-based drugs. In October 2021, Geniner raised an undisclosed amount of seed funding from new investor Korea Tech Incubator for Startup, being selected for Accelerator Investment-Driven Tech Incubator Program. Geniner specializes in animal vaccine development, focusing on infectious bronchitis, avian influenza, Escherichia coli, and salmonella. The company utilizes bacteriophage technology to create advanced biologics and antibodies, enabling more effective treatment for animals.
Additionally, the firm also provides tailored vaccine formulations for specific veterinary applications.
Current Investors
Seoul Technology Holdings, Korea Tech Incubator for Startup
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development, Medicinal Chemicals & Botanicals
Verticals
Manufacturing
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.